IPO round-up: K2M ups IPO target, but Lombard and Quotient aim lower
This article was originally published in Clinica
Contrary to the trend of medtech companies falling short of their IPO hopes, spinal device specialist K2M has increased the target for its initial public offering. The company said in March that it was hoping to raise $100m – but is now aiming for up to $158m. It said in a filing with the US Securities and Exchange Commission (SEC) that it plans to sell 8.8 million shares at $16-18 each. This total could rise further, with the underwriters having a 30-day option to purchase another 1.3 million shares.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.